Biogen’s Olivier Danos Joins Regenxbio as Chief Scientific Officer

Xconomy Boston — 

Olivier Danos is joining Regenxbio (NASDAQ: RGNX) to become the company’s chief scientific officer. Danos comes to the Rockville, MD, gene therapy biotech from Cambridge, MA-based Biogen (NASDAQ: BIIB), where he was the senior vice president of cell and gene therapy. Before joining Biogen, Danos was the senior vice president of molecular medicine, synthetic biology, and gene regulation at Kadmon Pharmaceuticals.